	Catalent Biologics announced on June 15, 2020 that it will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, for the large-scale commercial manufacturing of the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate, AZD1222.

	Under the terms of the agreement, Catalent will enable the facility for round-the-clock manufacturing schedules and will work to supply doses of the vaccine candidate from August 2020 potentially through to March 2022 if it is approved by regulatory agencies, a Catalent press release said.

	"Catalent has significant experience in the tech transfer and rapid scale-up of vaccine programs to meet demand," said Alessandro Maselli, president and chief operating officer of Catalent, in the press release. “Our manufacturing site in Anagni, Italy, has served for many years as a primary launch facility for new medicines, and the plant’s skilled team will take great pride in preparing to manufacture this vaccine candidate for COVID-19 and ensuring that the product will be able to reach patients as quickly as possible if approved.”

COVID-19 Update

Deals, Development and Manufacturing

PharmTech News

Supplier News

Vaccines

Catalent will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, for the large-scale commercial manufacturing of the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate.